Color Key for Poster Sessions:
Malaria-pink HAT-green Leishmaniasis-orange Chagas-blue

RSTMH Centenary Meeting
DNDi Partner Sessions and Sessions of Interest

Oral Sessions

Thursday, September 13:

11:45 – 12:24 CHALLENGES FOR INTERNATIONAL HEALTH
Chair: R. Horton

11:45
"**From science to health"**
Professor Mark Walport, The Wellcome Trust, UK

12:05
"Achieving health for all in the poorest countries"
Professor Jeffrey Sachs, Earth Institute, Columbia, USA

12:25
Title to be confirmed
Rt Hon Hilary Benn, Secretary of State for International Development, UK

Friday, September 14:

08:30 – 10:30 COMBATING MALARIA
Chair: W. Kilama

08:30
"Advances in the treatment of malaria"
Nick White, Mahidol University, Thailand

09:00
"A paradigm shift for malaria and dengue vector control"
Janet Hemingway, Liverpool School of Tropical Medicine and Hygiene, UK

09:30
"Clinical development of malaria vaccines"
Pedro Alonso, Universitat de Barcelona, Spain

10:00
"Perfusion abnormalities in children with cerebral malaria and malarial retinopathy"
NAV Beare[1,2]*, SP Harding[2], TE Taylor[3], S Lewallen[4], ME Molyneux[2]; [1]St Paul's Eye Unit, Royal Liverpool University Hospital, UK [2]Malawi-Liverpool-Wellcome Clinical

Color Key for Poster Sessions:
Malaria-pink HAT-green Leishmaniasis-orange Chagas-blue

Research Programme, Malawi [3]College of Osteopathic Medicine, Michigan State University, USA [4]Kilimanjaro Centre for Community Ophthalmology, Tanzania

10:15
"Randomised controlled trial of intermittent preventive treatment in schoolchildren: Impact on malaria, anaemia & school performance"
SE Clarke[1], MCH Jukes[2], JK Njagi[3], L Khasakhala[4], C Crudder[1], J Otido[5], B McGlone[1], BBA Estambale[5]*, S. Brooker[1]; [1]London School of Hygiene and Tropical Medicine, UK; [2]Harvard University, USA; [3]Division of Malaria Control, Ministry of Health, Kenya; [4]African Mental Health Foundation, Kenya; [5]University of Nairobi Institute for Tropical & Infectious Diseases, Kenya

12:45 – 13:45 CLINICAL SESSION 2

"How I manage severe malaria in Kenya"
Samuel Akech, Kenya Medical Research Institute, Kenya

"How I manage visceral leishmaniasis in India"
Shyam Sundar, Banaras Hindu University, India

16:30 – 17:30
"Tropical Disease Research Symposium"
Dr. Robert Ridley, Dr. Jane Kengeya Kayondo

Saturday, September 15:

09.00 – 10.30 CONTROL OF MAJOR INFECTIONS THROUGH COMMUNITY PROGRAMMES – Round Table Discussion
Led by A. Asamoa-Bach and David Molyneux

09:00 – 10:30
"Drug Donation Programmes: bridging pharmaceutical donors, national control programmes, NGDOs & WHO in the control of neglected tropical diseases"
Nana Twum-Danso, The Task Force for Child Survival and Development, USA

12.00 – 12.20 THE FUTURE OF TROPICAL MEDICINE
"Economics and tropical medicine: origins, current status and future developments"
Anne Mills, London School of Hygiene and Tropical Medicine, UK

Color Key for Poster Sessions:
Malaria-pink HAT-green Leishmaniasis-orange Chagas-blue

Poster Sessions

Poster Session 1
Friday, September 14, 2007
14.00 – 15.30

Poster Number	Abstract	Authors
[P1.3]	The role of oxidative stress and malaria infection on anaemia in pregnancy in southwestern Nigeria	O.M. Akanbi*[1], A.B. Odaibo[2], R. Olatoregun[1], O.G. Ademowo[2], [1]Adekunle Ajasin University, Nigeria; [2]University of Ibadan, Nigeria
[P1.7]	Interventions against pneumonia, malaria and lymphatic filariasis in Papua New Guinea	M.P. Alpers*, I.D. Riley, D. Lehmann, B. Genton, I. Betuela, I. Felger, H.P. Beck, J.W. Kazura, M. Bockarie, Pneumonia Malaria and Filariasis Research Teams, Institute of Medical Research, Papua New Guinea
[P1.8]	Comparative features and outcomes of malaria at a tertiary-care hospital in Karachi, Pakistan	M. A. Beg*, N. Sani, V. Mehraj, W. Jafri, A. Malik, E. Menezes, Aga Khan University, Pakistan
[P1.11]	Evaluation of malaria-control measures and efficacy of its treatment in paediatric patients at Shirati KMT Hospital, Tanzania	R. Bali*[1], R. Patel[1], B. Chirangi[2], E. Mahmoud[1], [1]Touro University, USA, [2]Shirati Hospital Medical Research Centre; Tanzania
[P1.16]	Phase III trial of pafuramidine maleate (DB289), a novel, oral drug, for treatment of first stage sleeping sickness	C. Burri*[1], S. Bernhard[1], C. Olson[2], A. Mpanya Kabeya[3], J.P. Fina Lubaki[4], G. Pohlig[1], [1]Swiss Tropical Institute, Switzerland; [2]Immtech Pharmaceuticals Inc., USA; [3]Programme Nationale de Lutte contre la Trypanosomiase Humaine Africaine, Congo; [4]Evangelic Hospital Vanga, Congo
[P1.17]	Childhood American cutaneous leishmaniasis: immunological parameters	M. Cabrera, N. Chirinos, S. Ferreira, G. Terán-Ángel, R. Silva*, O. Zerpa, Universidad Central de Venezuela, Venezuela
[P1.18]	The physiology and immunology of pregnancy and how they relate to tropical infectious diseases	I.D. Carroll*[1], D. Williams[2], [1]The Pregnant Traveller, USA; [2]Kings Norton Surgery, UK

Color Key for Poster Sessions:
Malaria-pink HAT-green Leishmaniasis-orange Chagas-blue

Poster Number	Abstract	Authors
[P1.23]	Cost-effective strategies for targeted Chagas disease control in the Andean region	C.R. Davies*[1], M. Castillo-Riquelme[1], F. Guhl[2], D. Campbell-Lendrum[1], Z. Chalabi[1], J. Lord[3], D. Feliciangeli[4], V.M. Angulo[5], M. Restrepo[6], J. Fox-Rushby[7], [1]London School of Hygiene and Tropical Medicine, UK; [2]Universidad de Los Andes, Colombia; [3]National Institute for Health and Clinical Excellence, UK; [4]Universidad de Carabobo, Maracay, Venezuela; [5]Universidad Industrial de Santander, Bucaramanga, Colombia; [6]Instituto Colombiano De Medicina Tropical, Medellin, Colombia; [7]Brunel University, UK
[P1.30]	Efficacy of a therapeutic DNA vaccine against *Trypanosoma cruzi* infection in dogs	I.A. Quijano-Hernandez*, M.E. Bolio-Gonzalez, J.C. Rodriguez-Buenfil, M.J. Ramirez-Sierra, E. Dumonteil, Universidad Autonoma de Yucatan, Mexico
[P1.35]	Baseline assessment of knowledge, attitude and practice of population in malaria-endemic zone in Bangladesh about malaria control and treatment-seeking behaviour	Faiz*, E. Yunus, R. Rahman, A. Hussaain, Z. Sharif, Z. Begum, Malaria Research Group, Bangladesh
[P1.36]	Comparison of quinine versus co-artem as follow up oral treatment following parenteral quinine in the management of severe malaria	Faiz*, E. Yunus, R. Rahman, A. Hussain, R. Samad, Z. Begum, Malaria Research Group, Bangladesh
[P1.42]	HIV–leprosy coinfected cases attending the outpatient's clinic at Agra, India: case report of 14 patients	T. Hussain*, K. Katoch, National JALMA Institute for Leprosy and Other Mycobacterial Diseases (Indian Council of Medical Research), India
[P1.44]	The West African network II for monitoring anti-malarial treatment (WANMAT II)	I.V. Valea*[1], R.T.G. Guiguemde[1], H.C. Counihan[2], J.B.O. Ouedraogo[3], [1]WANMAT II, Burkina Faso; [2]Malaria Consortium, UK; IRSS, Burkina Faso
[P1.46]	The efforts of NIPRD towards local production of Artemisinin-based Combination Therapy (ACTs) in combating malaria in Nigeria	I.A. Jegede*[1], A. Brisibe[2], J.I. Okogun[1], A.T. Orisadipe[1], Y. Kunle[1], U.S. Inyang[1], [1]Bradford University, UK; NIH, USA; Ahmadu Bello University, Nigeria

Color Key for Poster Sessions:
Malaria-pink HAT-green Leishmaniasis-orange Chagas-blue

Poster Number	Abstract	Authors
[P1.62]	Pulmonary complications in Chagas disease: experimental findings and possible impact in the perinatal mortality in endemic regions	V. Melnikov*, O. Dobrovinskaya, O. Newton-Sanchez, A. Maldonado-Rodriguez, F. Guzman-Rodriguez, F. Espinoza-Gomez, Colima University, Mexico
[P1.64]	Study of lymphoid and myeloid phenotypes and intracellular cytokines in visceral leishmaniasis (vl) patients	T.M. Mohapatra*, K. Bharti, M.R. Sen, S. Sunder, Institute of Medical Sciences, India
[P1.68]	The South African malaria initiative: an African response to an African problem	Z.G Ngcete[1,2] A. I. Louw[1,2] , E. J. Morris[1,2, 3, 4, 5], [1]South African Malaria Initiative; [2]University of Pretoria, South Africa; [3]African Centre for Gene Technologies; [4]CSIR; [5]University of the Witwatersrand, South Africa
[P1.69]	The impact of malaria and HIV coinfection in an urban setting of Cameroon	T.K. Nkuo Akenji*, E. Tevofouet, F. Nsang, N. Ngufor, University of Buea, Cameroon
[P1.71]	Malaria case management in under-5 children at public primary healthcare facilities in Tanzania	S. Nsimba*, A. Massele, J. Eriksen, MUCHS, Tanzania
[P1.73]	Recrudscence-reinfection discrimination, and discordant association between parasitological failure and markers of chloroquine resistance in Nigerian children with acute uncomplicated falciparum malaria	Y.A. Olukosi[1], A.O Magbagbeola[1], B.A Iwalokun[2], I.A. Akinwande[1], P.U. Agomo[1], O.O Aina1, C. Agomo[1], [1]Biochemistry Dept, College of Medicine, University of Lagos;[2] Biochemistry Dept, Lagos State University; [3]Biochemistry & Nutrition Dept, Nigerian Institute of Medical Research, Lagos
[P1.77]	HIV-1 and helminth coinfection in Kenya is correlated with socio-economic factors	C. Page*[1], J. Walson[2], P. Otieno[3], G. John-Stewart[2], [1]Yale School of Medicine, USA; [2]University of Washington Seattle, USA; [3]Kenya Medical Research Institute, Kenya
[P1.81]	Changes in membrane potential expressed by drug-resistant Leishmania might serve as a marker of chemo-resistance with prognostic value	E. Díaz, C. Machuca, M. Padron-Nieves, A. Romero, A. Ponte-Sucre*, Universidad Central de Venezuela, Venezuela

Color Key for Poster Sessions:
Malaria-pink HAT-green Leishmaniasis-orange Chagas-blue

Poster Number	Abstract	Authors
[P1.84]	Two longitudinal cohort studies investigating mechanisms of innate and acquired immunity to malaria in children from highly endemic regions of Papua New Guinea	L.J. Robinson[1], M.C. D'Ombrain[1], E. Lin[2], J. Taraika[2], N. Bernard[1], P. Michon[2], Y-U. Kwon[3], P. H. Seeberger[3], C.L. King[4], J.G. Beeson[1], D.I. Stanisic[1,2], I. Mueller[2], L. Schofield[1] [1]The Walter & Eliza Hall Institute of Medical Research, Australia; [2]Papua New Guinea Institute of Medical Research, Papua New Guinea; [3]Federal Institute for Technology (ETH) Switzerland; [4]Center for Global Health and Diseases, Case Western Reserve University, USA
[P1.89]	Self-treatment with chloroquine in rural communities of Tanzania: a therapeutic challenge for any future malaria treatment policy change in Tanzania	Shehoza*, S. Nsimba, Muhimbili University, Tanzania
[P1.94]	Bone marrow cell transplantation to the myocardium is safe and potentially effective in patients with heart failure due to Chagas Disease cardiomyopathy	R. Ribeiro dos Santos*[1], F. Vilas-Boas[2], G.S. Feitosa[2], M.B.P. Soares[1], J.A. Pinho-Filho[2], A. Andrade[2], [1]Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz, Brazil; [2]Hospital Santa Izabel, Brazil
[P1.103]	Clinical and epidemiologic presentation of acute Chagas disease in outbreaks related to oral transmission, Brazil – 2005/2006 – preliminary data	E. Tatto*, S. O. Santos, S. M. Oliveira, M. T. Obara, J. C. Silva, M. Flores, Secretariat of Health Surveillance (SVS), Ministry of Health (MoH), Brazil
[P1.104]	Development of age-based dose regimens for a new fixed-dose Artesunate-mefloquine combination for uncomplicated falciparum malaria	D.J. Terlouw*[1], D.J. Hayes[1], I. Ribeiro[2], F.O. ter Kuile[3], [1]Liverpool School of Tropical Medicine, UK; DNDi, Switzerland; US Centers for Disease Control and Prevention, USA
[P1.107]	Malaria quick impact in Suriname: millennium development goals (MDG) achieved	L. Villegas*[1], E. Commissie[2], H. Hiwat[2], J. Nieuwendam[2], G. Lavenberg[2], S. Mitro[2] [1]Consultant/Adviser Global Fund Malaria Program –Suriname; [2]Medical Mission -Global Fund Malaria Program – Suriname

Color Key for Poster Sessions:
Malaria-pink HAT-green Leishmaniasis-orange Chagas-blue

Poster Number	Abstract	Authors
[P1.111]	Elimination of malaria transmission in Sri Lanka: a possible second chance	A.R. Wickremasinghe*, D.R. Wickremasinghe, Faculty of Medicine, University of Kelaniya, Sri Lanka
[P1.114]	Leishmania major magnesium transporters are virulence factors	Y. Zhu*, T. Davis, J. Curtis, E. Handman, The Walter and Eliza Hall Institute of Medical Research, Australia

Poster Session 2
Friday, September 14, 2007
15.30 – 17.00

Poster Number	Abstract	Authors
[P2.2]	Enhancement of *in vivo* antimalarial activity of pyronaridine by promethazine in a mouse model	O.O. Abiodun*[1], G.O. Gbotosho[1], C.T. Happi[1], M.O. Falade[1], A.M.J. Oduola[2], [1]University of Ibadan, Nigeria; [2]Special Program for Research and Training in Tropical Diseases (WHO/TDR), Switzerland
[P2.3]	Artesunate plus sulfadoxine–pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria during pregnancy in eastern Sudan	Adam*[1], D. Ali[2], M. Abdalla[1], [1]University of Khartoum, Sudan; [2]New Halfa Hospital, Sudan
[P2.5]	Malaria transmission in the western Kenya highlands: the impact of land use changes	Y.A Afrane*[1], B.W. Lawson[1], A.K. Githeko[2], G. Yan[3], [1]Kenya Medical Research Institute, Kenya; [2]Kwame Nkrumah University of Science and Technology, Ghana; [3]University of California at Irvine, USA
[P2.19]	Three new drugs for leishmaniasis: the story of liposomal amphotericin, miltefosine and paromomycin	A. Bryceson*, J. Berman, W. Gutteridge, J. Karbwang, London School of Hygiene and Tropical Medicine, UK
[P2.21]	Immunolocalization of actin in the different stages of *Trypanosoma cruzi*	A.M. Cevallos*[1], Y.X. Segura-Kato[1], H. Merchant-Larios[1], R. Manning-Cela[2], I. Lopez-Villasenor[1], R. Hernandez[1], [1]UNAM, Mexico; CINVESTAV, Mexico

Color Key for Poster Sessions:
Malaria-pink HAT-green Leishmaniasis-orange Chagas-blue

Poster Number	Abstract	Authors
[P2.22]	High malaria self-treatment in adolescent girls in rural Malawi	G.K. Chapotera*[1], B.J. Brabin[1,2], [1]Liverpool School of Tropical Medicine, UK; [2]Royal Liverpool Children's NHS Trust, UK
[P2.30]	A cluster randomised trial to test the impact of deltamethrin dog collars on the incidence of zoonotic visceral leishmaniasis in Iran	C.R. Davies*[1], A.S. Mazloumi Gavgani[2], [1]London School of Hygiene & Tropical Medicine, UK; [2]Tabriz University of Medical Sciences, Iran
[P2.31]	Investigation of IFN-γ responsiveness in a longitudinal cohort of malaria-exposed, semi-immune Papa New Guinean children	M.C. D'Ombrain*[1], L.J. Robinson[1], C. King[2], D. Stanisic[1], I. Mueller[3], L. Schofield[1], [1]The Walter & Eliza Hall Institute of Medical Research, Australia; [2]Case Western Reserve University, USA; [3]Papua New Guinea Institute of Medical Research, Papua New Guinea
[P2.32]	Inflammatory mononuclear phagocyte in leishmaniasis: phenotypes and adhesion-molecule expression	M.D.E-R. Hermida, R. Malta, M.P. Macedo, M.A. Maciel, J.O. Mengel, W.L.C. dos-Santos*, Centro de Pesquisas Goncalo Moniz-Fundacao Oswaldo Cruz, Brazil
[P2.45]	Authentication of antimalarial drug formulations for use in Africa	H. Kaur, London School of Hygiene & Tropical Medicine, UK
[P2.48]	Leishmania major trans-glycosylation	A. Khabiri, Pasteur Institute of Iran, Iran
[P2.55]	The millennium goals need new vaccines and drugs for HIV, malaria and TB. Are we ready and able to conduct the trials in developing countries to truly assess the new drugs and vaccines coming through the development pipelines?	T. Lang*[1,2], K. Marsh[1,2], [1]KEMRI-WELLCOME Programme, [2]Kenya; University of Oxford, UK
[P2.57]	Study of the risk of introduction of the cutaneous leishmaniasis into the area of Sidi Slimane (Province of Kénitra)	L. Majda*[1], B. Driss[2], R. Mohammed[1], L. Mohammed[1], O. Souad1, [1]Institut National Hygiène in Rabat , Morocco;University Ibn Tofail Kénitra , Morocco

Color Key for Poster Sessions:
Malaria-pink HAT-green Leishmaniasis-orange Chagas-blue

Poster Number	Abstract	Authors
[P2.60]	Differential cytokine responses of peripheral blood mononuclear cells from new world cutaneous leishmaniasis patients and subjects vaccinated with a first generation vaccine to crude and defined *Leishmania amazonensis* antigens	R. B. Azeredo-Coutinho[1], D. Matos[1], G. Armôa[1], A. Schubach1, W. Mayrink[1], S. Mendonça*[1,2], [1]Fundação Oswaldo Cruz, Brazil;Universidade Federal de Minas Gerais, Brazil
[P2.63]	Evaluation and validation of immuno-diagnostic tests for kala-azar	T.M. Mohapatra*, K. Bharti, M.R. Sen, S. Sunder, Institute of Medical Sciences, India
[P2.64]	Predictors of poor outcome in malaria- A clinical study in a tertiary referral centre in a malaria-endemic area, Kolar District, India	N. Moorthy*, P.N. Venkatarathnamma, Sri Devaraj Urs Medical college and RLJ Hospital and Research Centre, India
[P2.69]	How sulfadoxine-pyrimethamine (SP) was perceived in rural communities of Tanzania after phasing out chloroquine as a first-line drug for uncomplicated malaria	S. Nsimba, Muhimbili University College of Health Sciences (MUCHS), Tanzania
[P2.72]	Evaluation of different protocols for the elicitation of murine immune responses to a new *Leishmania chagasi/infantum* recombinant antigen	L.R. dos Santos*[1,2], R.E. Fraga[1,2], A.M. Pereira[2], D.M. Santos[1], V.C. Sant'Ana Filho[1], L.C. Pontes-de-Carvalho[2], G.G.S. Oliveira[2], [1]Fundacao Oswaldo Cruz, Brazil; [2]Universidade Federal da Bahia, Brazil
[P2.81]	A model for the impact of intermittent preventive treatment in infants on malaria morbidity and mortality	A. Ross*, N. Maire, M. Penny, A. Studer, T. Smith, Swiss Tropical Institute, Switzerland
[P2.83]	Neonatal malaria: Probable immune system modulation by *Plasmodium falciparum* infection	Khalil, Khartoum, Sudan
[P2.93]	Effect of pre-treatment chloroquine levels on parasitological response in children with acute uncomplicated malaria	A. Sijuade*, G. Gbotosho, T . Happi, A. Sowunmi, A. Oduola, WHO, Switzerland
[P2.94]	Human visceral leishmaniasis: risk factors of acquiring the disease in Margarita Island, Venezuela	R.R. Silva Basanta*[1], R. Borges[2], M. Ulrich[2], [1]Universidad Central de Venezuela, Venezuela; [2]Instituto de Biomedicina, Venezuela

Color Key for Poster Sessions:
Malaria-pink HAT-green Leishmaniasis-orange Chagas-blue

Poster Number	Abstract	Authors
[P2.95]	CD2-induced T-cell proliferation – an emerging trend in immune therapy against visceral leishmaniasis	S. Sinha*[1], S. Bimal[2], S. Sundaram[1], [1]Allahabad University, India; [2]Rajendra Memorial Institute of Medical Sciences, India
[P2.98]	Creating a global database of antimalarial resistance	C.H. Sibley[1], C.J. Sutherland[2], C. Roper*[2], [1]University of Washington, USA; [2]London School of Hygiene & Tropical Medicine, UK
[P2.101]	Handbook of diagnosis, treatment and follow-up recommendations for *Trypanosoma cruzi*–HIV coinfection	S. O. Santos[1]*, E. Tatto[1], A. N. Ramos Jr[2], M. F. Simão[3], M. A. Shikanai-Yasuda[4], G. F. Pereira[1] [1]Secretariat of Health Surveillance (SVS), Ministry of Health (MoH),–Brazil; [2] Federal University of Ceará; [3]Federal University of Uberlândia; [4]São Paulo University, Brazil
[P2.107]	Therapeutic efficacy of chloroquine for uncomplicated *Plasmodium vivax* malaria in Sri Lanka	R. Wickremasinghe*[1], G. Galappathy[2], A. Wickremasinghe[3], P. Ringwald[1], [1]University of Kelaniya, Sri Lanka; [2]Anti Malaria Campaign, Sri Lanka; [3]World Health Organization, Swaziland
[P2.111]	Potent antimalarial and transmission-blocking activities of a novel DNA-binding agent	S.K. Yanow*[1], L.A Purcell[2], A. Rodriguez[3], M. Lee[4], T.W. Spithill[2], G. Pradel[3], [1]Provincial laboratory of Public Health (Microbiology), Canada; [2]McGill University, Canada; [3]New York University, USA; [4]Hope College, USA